Related Experiment Video
Updated: Jun 30, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.3K
Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma
Zi-Yi Wang1, Bin Xu1, Lu-Na Wang1
1Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.
International Immunopharmacology
|March 16, 2024
Summary
The platelet-to-lymphocyte ratio (PLR) is linked to immunotherapy response in advanced liver cancer. A PLR below 100 indicates a better tumor response and longer progression-free survival, especially with bevacizumab and anti-PD-1 therapy.
Area of Science:
- Oncology
- Immunotherapy
- Hepatocellular Carcinoma Research
Background:
- Lymphocyte-related factors impact cancer survival.
- The role of lymphocyte factors in immunotherapy response is not fully understood.
Purpose of the Study:
- To investigate the association between lymphocyte-related factors and tumor response to immunotherapy in advanced hepatocellular carcinoma (HCC).
- To explore the prognostic value of these factors in different immunotherapy regimens.
Main Methods:
- Retrospective analysis of 208 patients with advanced HCC receiving first-line immunotherapy.
- Tumor response assessed by RECIST 1.1 and mRECIST criteria.
- Logistic and Kaplan-Meier analyses evaluated clinical factors, progression-free survival (PFS), and overall survival (OS).
Main Results:
- A platelet-to-lymphocyte ratio (PLR) < 100 was independently associated with a more favorable tumor response.
- Patients with PLR < 100 demonstrated longer PFS.
- PLR showed greater prognostic value in the bevacizumab + anti-PD-1 group compared to the TKI + anti-PD-1 group.
Conclusions:
- PLR is associated with tumor response and survival outcomes in patients undergoing immunotherapy for HCC.
- The combination of bevacizumab and anti-PD-1 therapy benefits from PLR as a prognostic marker.
